Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Showing 97–120 of 175
Aerska has secured $39 million in Series A funding to advance RNA interference therapies that cross the blood-brain barrier for neurodegenerative diseases including Alzheimer's and Parkinson's. The company's platform addresses a critical delivery bottleneck that has limited genetic medicine effectiveness in the central nervous system.
ProMIS Neurosciences presented preclinical vaccine data targeting misfolded proteins in ALS, Parkinson's, and Alzheimer's disease. The approach uses computational epitope selection to generate selective immune responses against pathogenic protein conformations implicated in neurodegeneration.
Korsana Biosciences has secured $175 million to develop KRSA-028, a monoclonal antibody for Alzheimer's disease that uses transferrin receptor-based shuttle technology to cross the blood-brain barrier more effectively than existing therapies. The approach addresses a fundamental delivery limitation in treating neurodegenerative diseases, with Phase 1 data expected in mid-2027.
Brain endothelial cell-derived extracellular vesicles (c-BEEVs) detected in cerebrospinal fluid serve as a measurable biomarker for vascular dysfunction affecting the brain and cognitive decline. This discovery enables earlier detection of neurovascular pathology before symptomatic cognitive loss.
Vertex Pharmaceuticals reported Phase 3 trial results showing povetacicept reduced proteinuria by 52% in IgA nephropathy patients, compared to 4.3% in placebo groups, with an FDA filing planned by March. This represents a shift toward upstream immune intervention in kidney disease, addressing the autoimmune dysfunction driving tissue damage rather than managing symptoms alone.
MBX Biosciences advanced its endocrine and metabolic pipeline with a successful FDA End-of-Phase 2 meeting for canvuparatide in chronic hypoparathyroidism, positioning a Phase 3 trial for 2026. The company's funding runway extends to 2029, supporting multiple programs targeting metabolic dysfunction and hormone regulation.
NKGen Biotech's Troculeucel, a patient-derived natural killer cell therapy, shows early Phase 1 signals of cognitive improvement in moderate Alzheimer's disease, with reduced blood markers of brain inflammation correlating with enhanced memory and thinking performance. This represents a mechanistic shift from symptom management toward mobilizing endogenous immune defenses to address disease progression.
Galimedix presented preclinical data on a prodrug formulation of its oral Alzheimer's candidate that achieves higher systemic drug exposure at lower doses by improving absorption efficiency. The advancement addresses a critical practical constraint in neurodegenerative disease treatment: long-term medication adherence and tolerability.
Celularity secured $35 million in non-dilutive funding through a licensing agreement for its placental biomaterials portfolio, allowing the company to refocus resources on therapies targeting fundamental aging mechanisms while maintaining manufacturing and royalty streams. This capital structure reflects a strategic shift within regenerative medicine toward specialization in aging biology rather than symptomatic disease treatment.
AlzeCure Pharma completed Phase Ib dosing of ACD856, demonstrating a wider-than-expected therapeutic window and safety profile across repeated higher doses. The completion positions the compound for Phase II trials and exploration across multiple neurological indications beyond Alzheimer's disease.
Cellular senescence—the accumulation of cells that cease dividing but resist death—has emerged as a primary target in longevity medicine due to evidence that clearing these cells extends healthspan and can address root causes of age-related disease. Senotherapeutics, including senolytics and senomorphics, are transitioning from preclinical studies to clinical trials, though significant challenges in biomarker standardization, cellular heterogeneity, and clinical efficacy remain.
Senotherapeutics—strategies that eliminate or reprogram senescent cells—represent a shift from broad-spectrum senolytic approaches toward precision interventions that target specific cell types and contexts. This progression directly addresses a fundamental mechanism of aging, offering potential to extend healthspan by restoring cellular function rather than relying solely on senescent cell elimination.
Restore Hyper Wellness is promoting NAD supplementation through IV and intramuscular delivery formats, capitalizing on significant year-over-year increases in consumer search interest for NAD-related therapies. The initiative positions NAD precursors and direct NAD administration as tools for cellular energy optimization, though clinical evidence supporting broad longevity claims remains limited.
Senescent fibroblasts depend on reduced glucose metabolism and maintained chaperone proteins for survival. Inhibiting pyruvate dehydrogenase selectively eliminates senescent cells, including therapy-induced senescent cancer cells, with synergistic enhancement when combined with chaperone inhibition.
Nuchido addresses NAD+ decline through targeted restoration of the salvage pathway rather than simple precursor replacement, supported by randomized controlled human trials demonstrating improvements in inflammation, glycation, and biological age markers. This systems-biology approach represents a maturation of the NAD+ intervention landscape toward mechanistic rather than marketing-driven solutions.
Niagen Bioscience launched Niagen Plus, a telehealth platform delivering prescription-only nicotinamide riboside (Niagen) via at-home subcutaneous injection. The injectable route is positioned to bypass first-pass hepatic metabolism and improve tissue bioavailability compared to oral administration.
BCL XL-PROTAC, a senolytic agent, selectively eliminates senescent cells in COPD airway tissue while promoting proliferation of healthy cells. This approach addresses a core driver of age-related lung disease and suggests a therapeutic pathway for restoring lung cell function in COPD patients.
TGFβ signaling emerges as the primary tumor-promoting mechanism within senescent cells induced by platinum chemotherapy in ovarian and lung cancers. Targeting this pathway selectively could preserve the therapeutic benefit of chemotherapy while blocking its pro-tumor effects, addressing a critical vulnerability in current cancer treatment.
Natural killer cells from older adults fail to clear senescent fibroblasts due to overactivation of the Cdc42 protein, which disrupts the cellular machinery required for releasing cytotoxic granules and producing ATP. Pharmacological inhibition of Cdc42 restores this clearing capacity and offers a potential therapeutic target for age-related disease driven by senescent cell accumulation.
Melatonin restores testosterone production in aging Leydig cells by addressing oxidative stress and mitochondrial dysfunction, offering a mechanism-based alternative to passive testosterone supplementation. This shift from symptom management to cellular repair has implications for age-related hormonal decline in men.
Pulmatrix and Eos SENOLYTIX are merging to develop PTC-2105, a candidate designed to modulate mitochondrial function and clear senescent cells in sarcopenia and metabolic disease. The transaction signals a fundamental shift in biopharma toward targeting aging biology directly rather than its downstream manifestations.
Younger mice demonstrate faster wound healing due to a more robust senescent cell response, while the accumulation of senescent cells with age paradoxically impairs regeneration. This reveals a temporal window in which senescent cell activation supports tissue repair before becoming detrimental.
Gut microbial composition significantly influences individual response to GLP-1 medications, with distinct bacterial patterns correlating to treatment efficacy and the ability of the microbiome to support metabolic signaling. This mechanism explains variable clinical outcomes and suggests microbiome profiling could predict responders before treatment initiation.
Aging T cells develop senescence characteristics that drive chronic inflammatory skin diseases through dysregulated signaling pathways and secretion of pro-inflammatory factors. Targeting senescent T cells or their signaling cascades offers a mechanism-based approach to achieving sustained remission in conditions like psoriasis and atopic dermatitis.
